|会社名||Pfizer Inc （PFE ファイザ―）|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 ファイザー（Pfizer Inc.）は研究ベースのグローバルなバイオ医薬品会社である。同社は医療製品の発見、開発、製造に従事する。グローバル・ポートフォリオには医薬品とワクチン、消費者向けの医療製品が含まれる。同社はファイザー・イノベーティブ・ヘルス（IH）とファイザー・エッセンシャル・ヘルス（EH）という2つの事業区分を通じて商業活動を管理する。IH事業は医薬品とワクチン、消費者向けのヘルスケア製品の開発と商業化を行う。IHの治療分野は内科、ワクチン、腫瘍学、炎症、免疫学、希少疾患と消費者医療を含む。EH事業にはレガシー・ブランド、ブランド・ジェネリック、一般的無菌注射用製品、バイオシミラーと輸液システムを含む他、研究・開発（R＆D）組織と契約製造事業を含む。ブランドは「Prevnar 13」、「Xeljanz」、「Eliquis」、「Lipitor」、「Celebrex」、「Pristiq」、「Viagra」を含む。 ファイザ―は米国大手医薬品メ―カ―。循環器系、中枢神経系、鎮痛・抗炎症系、筋骨格系、感染症、泌尿器系、眼科系、ガン、内分泌系、ワクチンの薬剤を開発、製造、販売。主要製品は｢セレブレックス｣、｢チャンテックス｣、｢リピト―ル｣、｢リリカ｣、｢プリスティ―ク｣、｢バイアグラ｣。抗感染、内分泌傷害、血友病、炎症、多発性硬化症の医薬品も展開。 Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.|
|本社所在地||235 East 42nd Street New York NY 10017 USA|
|代表者氏名||Ian C. Read|
|代表者役職名||Executive Chairman of the Board|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 Pfizer Inc. revenues increased 2% to $53.65B. Net income applicable to common stockholders excluding extraordinary items decreased 13% to $10.35B. Revenues reflect Operating Segment-Global Innovative Pharmaceutical increase of 6% to $33.43B Emerging Markets segment increase of 11% to $12.65B Developed Europe segment increase of 7% to $9.12B. Net income was offset by Impairment of Intangibles excl.|
EMA flexibiliza almacenamiento Pfizer y puede estar un mes en nevera normal 2021/05/17 16:34:00 Investing.com Spain
‘A mammoth undertaking’: Bolton steps up Covid jabs to tackle outbreak 2021/05/17 15:45:05 The Guardian
More than 6,200 people get vaccine dose as doctors take pragmatic approach on eligibility The race to tackle an outbreak in Bolton of the virulent new strain of Covid-19 first identified in India began with a flurry of phone calls on Thursday afternoon. The urgency at senior levels was clear to those on the ground, who were told: “If we throw every bit of Pfizer at you that we can find, how many [people] can you jab this weekend?” In one meeting, Michael Smith, the chief officer of Bolton’s GP federation, told NHS England they could jab 5,000 people in one weekend – eight times the average rate. “Everybody’s faces were a bit like: what? Really?” Continue reading…
Ema, ok a tempi conservazione più lunghi per vaccino Pfizer in frigoriferi normali 2021/05/17 15:27:55 Investing.com Italy
Microsoft Named 2020’s Most Conscious Brand, Beating Pfizer, Google and Amazon 2021/05/17 11:18:10 Adweek
Technology giant Microsoft topped a poll of the 100 most Conscious Brands of 2020. In a year where brands have been encouraged to offer more empathy as the Covid-19 pandemic gripped the world, Microsoft topped the global survey of 9,000 consumers rating 223 brands in the U.K., U.S. and China. The inaugural list was announced…
Here Is What You Can Expect At Major US Stores Following CDC's New Mask Guidance 2021/05/15 17:37:28 Benzinga
The Centers for Disease Control (CDC) has relaxed mask-wearing rules for those fully vaccinated against COVID-19. According to the CDC , fully vaccinated people can resume activities without wearing a mask or physically distancing, except where required by federal, state, local, tribal or territorial laws, rules and regulations, including local business and workplace guidance. The CDC says people are considered fully vaccinated two weeks after their second dose in a two-dose series, such as the Pfizer Inc. (NYSE: PFE ) or Moderna Inc (NASDAQ: MRNA ) vaccines, or two weeks after a single-dose vaccine, such as Johnson & Johnson's (NYSE: JNJ ) … Full story available on Benzinga.com
122 cr doses needed to inoculate 59 cr ppl: Centre 2021/05/02 09:22:20 Economic Times India
The Centre has told the Supreme Court that a total of 122 crore doses of COVID-19 vaccine would be required to vaccinate a population of 59 crore in the age group of 18 to 45 years. In an affidavit filed before the top court, the Centre said vaccination is the topmost priority of the government and all efforts are being made to achieve an objective of 100 per cent vaccination in the shortest time possible keeping the available resources in mind and availability of vaccine doses into consideration. "It is submitted that considering the limited availability of two vaccines which are presently available in India namely Covaxin and Covishield, it became incumbent upon the government to prioritise vaccination in the most scientific manner. It is submitted that while prioritising vaccination the first priority was towards health workers. "It is submitted that projected mid-year population for 2021 for the age group of 18 to 45 years is about 59 crore. To vaccinate this target, a total of 122 crore doses of COVID-19 vaccine would be required (which factors in some vaccine wastage which is inevitable)," the Centre said.
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates 2021/05/01 15:43:34 Benzinga
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) Nuplazid failed to get label expansion to include the indication of dementia-related psychosis. The FDA did not keep its tryst with the decision dates for ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) pain drug and Sol-Gel Technologies Ltd.'s (NASDAQ: SLGL ) investigational skin inflammation treatment. Protalix BioTherapeutics, Inc.'s (NASDAQ: PLX ) Fabry disease treatment candidate also faced rejection at the FDA altar. The regulatory agency extended the review period for Pfizer Inc.'s (NYSE: PFE ) atopic dermatitis drug. On the other hand, Supernus Pharmaceuticals, Inc.'s (NASDAQ: SUPN ) attention deficit hyperactivity drug cleared the FDA hurdle in its second attempt. And GlaxoSmithKline plc's (NYSE: GSK ) Jemperli, a new molecular entity, won the nod for advanced endometrial cancer. Another the NMEs approved during the month was ADC Therapeutics SA's (NYSE: ADCT ) Zynlonta in relapsed or refractory large B-cell lymphoma.
Two Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters 2021/04/30 17:46:25 Benzinga
According to a U.K. study, a single dose of Pfizer Inc (NYSE: PFE ) - BioNTech SE's (NASDAQ: BNTX ) coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, reports Reuters . The Imperial College-led study, which analyzed blood samples among healthcare … Full story available on Benzinga.com
Canada to start to get Pfizer vaccines from the US next week 2021/04/30 16:51:13 ABC News
Drug maker Pfizer says it will start sending U.S.-produced COVID-19 vaccines to Canada next week
BioNTech - Pfizer COVID-19 Shot Expected To Be Effective Against Double Mutants, Says BNTX CEO: CNBC 2021/04/30 16:33:32 Benzinga
BioNTech SE (NASDAQ: BNTX ) is “confident” that its COVID-19 vaccine with U.S. partner Pfizer Inc (NYSE: PFE ) is effective against a coronavirus variant first identified in India, CEO Ugur Sahin told CNBC . The B.1.617 strain, also referred to as the “double mutant,” was first spotted in India, and it contains two key mutations that have been found separately in other coronavirus variants. The variant is believed to be … Full story available on Benzinga.com
Esta es la vacuna que te pondrán según tu edad 2021/04/03 04:45:07 Business Insider Spain
Las vacunas de Pfizer, Moderna, AstraZeneca y Janssen se administrarán en función de la edad o condición de riesgo: esta es la que te corresponde.
Pfizer/BioNTech COVID-19 vaccine highly effective up to six months after second dose 2021/04/02 04:39:00 Business Insider India
The ongoing Phase 3 clinical trial of the Pfizer/BioNTech's Covid-19 vaccine showed that it remains highly effective for up to six months after the second
Company involved in 15 million discarded doses of the J&J vaccine has history of quality control violations 2021/04/02 00:27:19 Business Insider
Summary List Placement The company at the center of the mix-up that led to roughly 15 million discarded doses of the Johnson & Johnson vaccine has a history of quality control violations, the Associated Press reported. A manufacturing plant in Baltimore under Emergent Biosolutions, one of eight companies producing the Johnson & Johnson vaccine, spoiled a batch of the Johnson & Johnson vaccine , delaying production and halting future shipments, The New York Times reported Wednesday. The mishap was due to human error, according to The Times, when workers at the plant mixed up the vaccine ingredients. The Food and Drug Administration is currently investigating the incident. But the company has been cited on multiple occasions by the Food and Drug Administration for quality control issues, ranging from cracked vials and poorly trained employees to problems managing mold and other contaminants within one of its facilities, according to records obtained by AP through the Freedom of Information Act.
Pfizer updates efficacy data in wake of COVID variants 2021/04/01 21:52:47 Australian Broadcasting Corporation
Pfizer and BioNTech say their COVID-19 vaccine is about 91 per cent effective at preventing the disease, citing updated trial data that includes participants inoculated for up to six months.
UK Data Shows Substantial Immune Response With Pfizer COVID-19 Shot In Elderly 2021/04/01 18:02:31 Benzinga
According to real-world data in the U.K. , around 98% of elderly aged between 80 to 96 years who received two doses of Pfizer Inc’s (NYSE: PFE ) coronavirus vaccine had a strong antibody immune response, reports Reuters. A study of 100 older adults in Britain also found that vaccinated participants already had a peak antibody response after just one dose of the vaccine, and this response … Full story available on Benzinga.com
関連キーワード （医薬品 米国株 PFE ファイザ― PFE ）